End-to-end cell therapy automation

US11371018B2 · kind B2 · utility

Assignees

• OCTANE BIOTECH INC. · CA
• LONZA WALKERSVILLE, INC. · US
• Lonza Cologne GmbH · DE

Inventors

• Yaling Shi · Larkspur, US
• Erika MCAFEE · Walkersville, US
• Samatha Bandapalle · Walkersville, US
• Ann Siehoff · Cologne, DE
• Timo Gleissner · Euskirchen, DE
• Joseph O'Connor · Walkersville, US
• Eytan Abraham · Frederick, US
• Kelly Purpura · Kingston, CA
• Nuala TRAINOR · Kingston, CA
• Timothy Smith · Kingston, CA

Key dates

• Filing date: Oct 30, 2019
• Grant date: Jun 28, 2022
• Expiry date: Oct 30, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/15041
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.